Trump sent letters to 17 of the world’s largest drugmakers earlier this month, including Lilly and Novo Nordisk A/S, insisting they lower what they charge Medicaid in the U.S. for existing drugs.
The complaint alleges the Indianapolis-based drugmaker offered illegal incentives to influence Texas providers to prescribe Lilly medications including Zepbound and Mounjaro.
Eli Lilly and Co. has already launched LillyDirect service, which CEO David Ricks says jibes with the administration’s demand for direct sales. Lilly is working with Truepill and Amazon.com Inc.’s pharmacy unit on its platform.
The Indianapolis-based pharmaceutical giant released its second-quarter earnings Thursday along with data from the latest studies of its weight-loss pill, orforglipron.
Seven years of investigation by scientists at Harvard Medical School has revealed that the loss of the metal lithium plays a powerful role in Alzheimer’s disease, a finding that could lead to earlier detection, new treatments and a broader understanding of how the brain ages.
Seventeen of the complaints also name Eli Lilly and Co. competitor Novo Nordisk Inc. as a defendant and make similar allegations about its GLP-1 drug, Ozempic.
Trump administration officials have offered mixed messages about GLP-1s and whether they should be relied upon for weight loss by obese and overweight Americans.
A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results showed enough cardio benefits to eventually encourage investors.
Lilly previously secured approval for Kisunla in the U.S., Japan and the U.K.
The up-and-coming leaders represent business, the arts and culture, philanthropy, government and community service.
Partnerships between telehealth companies and pharmaceutical giants Pfizer and Indianapolis-based Eli Lilly and Co. raise concerns about conflicts of interest and inappropriate prescribing, according to a Senate investigation released Thursday.
The medications still amount to around $500 per month for those without insurance—out of reach for many patients. And even for people with insurance, coverage remains uneven.
The combination offers a potential solution to one of the key problems that’s emerged with popular obesity shots.
Questions included whether the Indianapolis-based drugmaker is working to improve insurance coverage for the drug and highlighted users’ concerns about comparisons with Novo Nordisk’s Wegovy.
Boston-based Verve Therapeutics is a Nasdaq-traded company focused on genetic medicines for cardiovascular disease.
The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other conditions because it comes in pill form, not an injection.
Persist AI announced a $12 million Series A funding round to support its new Cloud Lab platform, allowing companies to use its lab remotely for research and development.
Lilly in February announced plans to add four U.S. manufacturing sites at yet-to-be-determined sites as part of a roughly $27 billion investment.
SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and sensory hyperexcitability disorders.
On Thursday, pharmacies were supposed to stop making the copies of the medications that had become popular during shortages of the brand-name drugs.
